Results 121 to 130 of about 1,498,446 (168)
Some of the next articles are maybe not open access.
Efficacy of antiparkinson agents in preventing antipsychotic-induced extrapyramidal symptoms
American Journal of Health-System Pharmacy, 1979The types of extrapyramidal syndrome (EPS) reactions produced by antipsychotic agents and the prophylactic use of antiparkinson agents in preventing EPS are reviewed. EPS are classified as akathisias, dystonias, parkinson-like symptoms and tardive dyskinesia, and have a varied incidence reported to range from 10.6 to 100%.
Ronald B Stewart, John E Murphy
exaly +3 more sources
Some New Piperazino Derivatives as Antiparkinson and Anticonvulsant Agents
Archiv Der Pharmazie, 1983AbstractThe piperazino derivatives 1–7 were synthesized and evaluated for their antiparkinson activity on oxotremorine‐induced tremors and reserpine‐induced rigidity. The same compounds were screened for their anticonvulsant activity. Compounds 1, 3, 4 and 5 showed promising antiparkinson activity.
K Shanker, K P Bhargava
exaly +3 more sources
ANTIPARKINSON DRUGS AS CAUSAL AGENTS IN TARDIVE DYSKINESIA
Medical Journal of Australia, 1973L G Kiloh
exaly +3 more sources
Molecules, 2008 Parkinson`s disease (PD) is a progressive, neurodegenerative disorder whichinvolves the loss of dopaminergic neurons of the substantia nigra pars compacta.
Antonio di Stefano, Piera Sozio
exaly +2 more sources
POTENTIAL FOR ABUSE OF ANTIPARKINSON AGENTS
Psychiatric Services, 1982Hospital &‘ Community Psychiatrj is expanding its roster of peer reviewers for manuscripts submitted for publication. Professionals in the mental health disciplines who are qualified to serve as peer reviewers are invited to contact the editor. Reviewers must have significant publications in their specialty area, be abreast of the liteEature in that ...
James M. Smith, Winston W. Shen
openaire +2 more sources
Quantitative Determination of Some Synthetic Antiparkinsonism Agents
Journal of Pharmaceutical Sciences, 1968Nonaqueous titrimetry was employed to estimate quantitatively some of the compounds which are useful in treating Parkinsonism. The method was applied to both the crystalline material and their dosage forms. This technique was found to yield results which agreed well with those obtained by either the official procedures or by methods submitted by the ...
L G, Chatten, W J, Racz
openaire +2 more sources
New L‐Dopa Codrugs as Potential Antiparkinson Agents
Archiv der Pharmazie, 2008AbstractThis paper reports the synthesis and preliminary evaluation of newL‐dopa (LD) conjugates (1and2) obtained by joining LD with two different natural antioxidants, caffeic acid and carnosine, respectively. The antioxidant efficacy of compounds1and2was assessed by evaluating plasmatic activities of superoxide dismutase (SOD) and glutathione ...
SOZIO, Piera +9 more
openaire +4 more sources
[Immunotropic activity of a potential antiparkinson agent himantane].
Eksperimental'naia i klinicheskaia farmakologiia, 2001N-(Adamant-2-yl) hexamethyleneimine hydrochloride (A-7, himantane), a new potential antiparkinsonian drug belonging to the class of aminoadamantyl derivatives, exhibits pronounced immunomodulant activity in a therapeutic dose of 10 mg/kg. A single intraperitoneal injection of himantane stimulated a high B-lymphocyte activity in mice over a period of 21
G I, Nezhinskaia +3 more
openaire +2 more sources